Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Novartis AG released its Annual Report for 2024, alongside its ‘Novartis in Society – Integrated Report 2024.’ This announcement underscores the company ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...

Bank of America Securities analyst Graham Parry has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with ...

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.

Looking ahead to 2025, Novartis maintains an optimistic stance, forecasting mid to high single-digit sales growth and anticipating even stronger operational core earnings in the high single to low ...

The Japanese conglomerate is in talks to spend up to $43 billion to boost the ChatGPT developer. Novartis expects profit and sales to grow further this year after beating analysts' expectations, ...

Prices have likely climbed on a swift move from investors to safety due to Trump tariff threats, rising geopolitical tensions and U.S. government debt, and fear of a potential tech rout that could ...

Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

German automotive supplier Robert Bosch (ROBG.UL) said on Friday that its operating profit plummeted by a third to 3.2 ...

Procurement software demand is driven by digital transformation, AI, and sustainability, with key players like SAP Ariba and ...